These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19380280)

  • 1. The effects of physical exercise on plasma levels of relaxin, NTproANP, and NTproBNP in patients with ischemic heart disease.
    Heringlake M; Kox T; Poeling J; Klaus S; Hanke T; Franz N; Eberhardt F; Heinze H; Armbruster FP; Bahlmann L
    Eur J Med Res; 2009 Mar; 14(3):106-12. PubMed ID: 19380280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac peptides during exercise test in ischemic and non-ischemic heart failure patients.
    Ilea M; Zdrenghea D; Bodisz G; Mălai A; Gheorghiu L; Predescu D; Beudean M; Ossian V; Gligor E; Vlad C; Pop D; Bogdan E; Roşu R
    Rom J Intern Med; 2008; 46(1):63-8. PubMed ID: 19157272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of NT-proBNP, proANP and novel biomarkers: copeptin and proadrenomedullin with LVEF and NYHA in patients with ischemic CHF, non-ischemic CHF and arterial hypertension.
    Vondráková D; Málek F; Ošťádal P; Vránová J; Miroslav P; Schejbalová M; Neužil P
    Int J Cardiol; 2011 Aug; 150(3):343-4. PubMed ID: 21640398
    [No Abstract]   [Full Text] [Related]  

  • 4. NT-proANP and NT-proBNP as prognostic markers in patients with acute decompensated heart failure of different etiologies.
    Luers C; Sutcliffe A; Binder L; Irle S; Pieske B
    Clin Biochem; 2013 Aug; 46(12):1013-1019. PubMed ID: 23542086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure.
    Parovic M; Okwose NC; Bailey K; Velicki L; Fras Z; Seferovic PM; MacGowan GA; Jakovljevic DG
    ESC Heart Fail; 2019 Apr; 6(2):449-454. PubMed ID: 30788904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study.
    Felker GM; Whellan D; Kraus WE; Clare R; Zannad F; Donahue M; Adams K; McKelvie R; Piña IL; O'Connor CM;
    Am Heart J; 2009 Oct; 158(4 Suppl):S37-44. PubMed ID: 19782787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
    Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ;
    J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
    Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Hansen PM; Kamstrup PR; Faber J; Køber L; Schou M
    Biomarkers; 2020 May; 25(3):248-259. PubMed ID: 32126847
    [No Abstract]   [Full Text] [Related]  

  • 9. Determinants of absolute and relative exercise-induced changes in B-type natriuretic peptides.
    Maeder MT; Staub D; Surnier Y; Reichlin T; Noveanu M; Breidthardt T; Potocki M; Schaub N; Conen D; Mueller C
    Int J Cardiol; 2011 Mar; 147(3):409-15. PubMed ID: 19897258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [N-terminal pro-brain natriuretic peptide (NT-proBNP) and ischemia modified albumin (IMA) in exercise induced ischemia in patients with stable coronary artery disease].
    Piechota WN; Wierzbowski R; Piechota WT; Bejm J; Gielerak G
    Pol Arch Med Wewn; 2006 Jul; 116(1):640-7. PubMed ID: 17340970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
    Hauser JA; Demyanets S; Rusai K; Goritschan C; Weber M; Panesar D; Rindler L; Taylor AM; Marculescu R; Burch M; Wojta J; Michel-Behnke I
    Heart; 2016 Oct; 102(20):1633-9. PubMed ID: 27220692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers.
    Heringlake M; Heide C; Bahlmann L; Eichler W; Pagel H; Schmucker P; Wergeland R; Armbruster FP; Klaus S
    J Appl Physiol (1985); 2004 Jul; 97(1):173-9. PubMed ID: 14990550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise oscillatory breathing and NT-proBNP levels in stable heart failure provide the strongest prediction of cardiac outcome when combining biomarkers with cardiopulmonary exercise testing.
    Guazzi M; Boracchi P; Labate V; Arena R; Reina G
    J Card Fail; 2012 Apr; 18(4):313-20. PubMed ID: 22464773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of determined NT-proBNP in physical standardized exercise.
    Bartek J; Stejskal D; Lacnák B; Juráková R
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2003 Nov; 147(1):71-5. PubMed ID: 15034608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
    Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.
    Seronde MF; Gayat E; Logeart D; Lassus J; Laribi S; Boukef R; Sibellas F; Launay JM; Manivet P; Sadoune M; Nouira S; Solal AC; Mebazaa A;
    Int J Cardiol; 2013 Oct; 168(4):3404-11. PubMed ID: 23684562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure.
    Zelt JGE; Liu PP; Erthal F; deKemp RA; Wells G; O'Meara E; Garrard L; Beanlands RSB; Mielniczuk LM
    Can J Cardiol; 2017 Nov; 33(11):1478-1488. PubMed ID: 28966019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ProANP and proBNP in plasma as biomarkers of heart failure.
    Davidovski FS; Goetze JP
    Biomark Med; 2019 Sep; 13(13):1129-1135. PubMed ID: 31468978
    [No Abstract]   [Full Text] [Related]  

  • 20. Low NT-proBNP levels: An early sign for the diagnosis of ischemic heart failure.
    Zheng YR; Ye LF; Cen XJ; Lin JY; Fu JW; Wang LH
    Int J Cardiol; 2017 Feb; 228():666-671. PubMed ID: 27883979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.